Point72 Asset Management
NVCR icon

Point72 Asset Management’s NovoCure NVCR Stock Holding History

Point72 Asset Management’s Portfolio NVCR Stock Details NVCR Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2023
Q3 		– Sell
-15,000
Closed -$623K – 2754
2023
Q2 		$623K Buy
+15,000
New +$931K ﹤0.01% 1223
2023
Q1 		– Sell
-155,000
Closed -$11.4M – 2453
2022
Q4 		$11.4M Buy
+155,000
New +$11.7M 0.04% 509

Other funds holding NVCR

Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
SCM
Soleus Capital Management Greenwich, Connecticut $2.47B AUM 115.63% 1-Year Est. Return
VPM
Vanguard Portfolio Management Malvern, Pennsylvania $1.91T AUM
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
Wells Fargo
Wells Fargo San Francisco, California $530B AUM 22.01% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
QCM
Quantinno Capital Management New York $59.9B AUM 28.07% 1-Year Est. Return

Point72 Asset Management's NVCR Position: Q1 2026 in Review

Point72 Asset Management increased its NovoCure (NVCR) stake by 51% in Q1 2026, buying an estimated $5.76M and bringing the position to 1,361,391 shares worth $14.8M. The position accounts for 0.02% of the portfolio, ranked #987.

Point72 Asset Management first reported a position in NVCR in Q1 2019 and has held it in 10 quarters since. 223 funds tracked by Wall St. Rank hold NVCR as of Q1 2026.

  • Point72 Asset Management held 1,361,391 shares of NovoCure worth $14.8M as of Q1 2026.
  • Point72 Asset Management bought 460,895 NovoCure shares in Q1 2026, an estimated $5.76M.
  • NovoCure made up 0.02% of Point72 Asset Management's portfolio in Q1 2026, its #987 holding.
  • Point72 Asset Management first reported a position in NovoCure in Q1 2019 and has held it in 10 quarters since.
  • 223 funds tracked by Wall St. Rank held NovoCure as of Q1 2026.

Based on Point72 Asset Management's 13F filing for Q1 2026, filed 15 May 2026.